Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Automation
IT & Software
Return to: PBR Home | Automation | IT & Software

IT & Software

EyeGate gets USPTO notice of allowance for proprietary dexamethasone phosphate formulation Eyegate Pharmaceuticals (EYEG), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye, announced that it has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for a patent application related to its lead product candidate, EGP-437.
Automation > IT & Software > News
Pulmatrix issued patents covering iSPERSE technology to treat patients with inhaled dry powders Pulmatrix (PULM) has been granted two patents from the US Patent and Trademark Office (U.S. Patent # 8,992,983 and US patent # 9,061,352), which cover the composition of matter for the company's underlying iSPERSE (inhaled Small Particles Easily Respirable and Emitted) inhaled dry powder technology as well as methods for treating a subject using respirable dry powders.
Automation > IT & Software > News Acorda awarded grant to study ARCUS Technology in respiratory distress syndrome Acorda Therapeutics announced that the Bill & Melinda Gates Foundation has awarded the Company a $1.4m grant to support the development of a formulation and delivery system for a dry powder version of lung surfactant, a drug used to treat neonatal respiratory distress syndrome (RDS).
Automation > IT & Software > News
See more IT & Software news

Latest IT & Software News and Insight

View all IT & Software news or find news targeted to your interests
Medimmune, Sheffield University to research in cell factory technology
By PBR Staff Writer
AstraZeneca's global biologics R&D arm MedImmune has entered into a five-year multi-project research collaboration with the University of Sheffield to carry out breakthrough research in cell factory technology process.
Automation > IT & Software > News
Eisai, JCR to discover new CNS treatments using BBB penetration technology
By PBR Staff Writer
Eisai and JCR Pharmaceuticals have concluded a feasibility study agreement, which will examine the possibility of applying JCR's blood-brain-barrier (BBB) penetration technology 'J-Brain Cargo' to discover new treatments.
Automation > IT & Software > News
ContraFect gets key patent from USPTO covering new Lysin technology
ContraFect Corporation, a biotechnology company focused on the discovery and development of protein therapeutics and antibody products for life-threatening, drug-resistant infectious diseases, announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 9,034,322.
Automation > IT & Software > News
Cellecta receives NIH SBIR grant to develop validated CRISPR knockout library of guide RNA (sgRNA) sequences
Cellecta, a US-based functional genomics company, announces the receipt of Phase I SBIR grant funds from the National Institute of Health (NIH) to further its CRISPR-mediated genome-editing program.
Automation > IT & Software > News
NantHealth acquires Harris Healthcare Solutions
NantHealth, a subsidiary of NantWorks, announced it has completed the acquisition of Harris Corporation’s commercial Healthcare Solutions business, a clinical systems integration innovator. Harris retained its government healthcare services business.
Automation > IT & Software > News
Amgen reports Phase II trial results of Blincyto in patients with Ph+ B-cell precursor ALL
By PBR Staff Writer
Amgen has reported positive top-line results from an investigational Phase II trial, which was designed to evaluate the efficacy and safety of Blincyto (blinatumomab) in adults with relapsed or refractory Philadelphia chromosome-positive (Ph+) B-cell precursor acute lymphoblastic leukemia (ALL).
Automation > IT & Software > News
Panther closes acquisition of technology assets of Faulk Pharmaceuticals
Panther Biotechnology, a biotechnology company specializing in the acquisition and development of enhanced therapeutics for the treatment of neoplastic, autoimmune and antiviral disorders, is pleased to announce that it has closed definitive agreements with privately held Faulk Pharmaceuticals to acquire Faulk's pharmaceuticals technology assets.
Automation > IT & Software > News
Argos completes patient enrollment in Phase III ADAPT trial of AGS-003
Argos Therapeutics, an immuno-oncology company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer based on the Arcelis technology platform, announced the pivotal phase 3 ADAPT clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma (mRCC) has reached its enrollment goal of at least 450 randomized patients.
Automation > IT & Software > News
Medgenics begins enrollment in Phase II trial of TARGT-EPO to treat anemia in ESRD patients
By PBR Staff Writer
Medgenics has started patient enrollment in its US-based Phase II clinical trial of MDGN-201 (TARGTEPO), an investigational gene therapy to treat anemia in end stage renal disease (ESRD) patients undergoing peritoneal dialysis.
Automation > IT & Software > News
OmniComm Systems signs reseller agreement with Tri-I Biotech Shanghai
OmniComm Systems, a global leading provider of clinical data management technology and services, today announced that it has signed a reselling partnership agreement with Tri-I Biotech Shanghai, a market leading China based consultancy providing high performance informatics solutions to over 1,000 medical and clinical research organizations across China, Hong Kong, Macau and Taiwan.
Automation > IT & Software > News
View all IT & Software news or find news targeted to your interests